ULBP2 polypeptides
    1.
    发明授权
    ULBP2 polypeptides 失效
    ULBP2多肽

    公开(公告)号:US08410252B2

    公开(公告)日:2013-04-02

    申请号:US12862629

    申请日:2010-08-24

    摘要: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-γ production, NK cell proliferation, and CTL activity.

    摘要翻译: 本发明涉及纯化和分离的新型ULBP多肽,编码此类多肽的核酸,生产此类多肽的重组形式的方法,针对这些多肽产生的抗体,衍生自这些多肽的片段化肽以及上述用途。 ULBP多肽可以在人B细胞淋巴瘤的表面上发现。 提供分离或纯化形式的ULBP多肽的哺乳动物形式。 此外,提供了编码ULBP多肽的分离的核酸和包含编码ULBP多肽的cDNA的表达载体。 ULBP多肽可以被分离或合成并用于制备针对多肽的抗体,特别是单克隆抗体。 抗体又可用于检测人细胞样品中ULBP多肽的存在,这可与患者中恶性病症的存在相关。 ULBP多肽刺激IFN-γ产生,NK细胞增殖和CTL活性。

    ULBP antibodies
    3.
    发明授权
    ULBP antibodies 失效
    ULBP抗体

    公开(公告)号:US07193058B2

    公开(公告)日:2007-03-20

    申请号:US10875869

    申请日:2004-06-23

    摘要: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-γ production, NK cell proliferation, and CTL activity.

    摘要翻译: 本发明涉及纯化和分离的新型ULBP多肽,编码此类多肽的核酸,生产此类多肽的重组形式的方法,针对这些多肽产生的抗体,衍生自这些多肽的片段化肽以及上述用途。 ULBP多肽可以在人B细胞淋巴瘤的表面上发现。 提供分离或纯化形式的ULBP多肽的哺乳动物形式。 此外,提供了编码ULBP多肽的分离的核酸和包含编码ULBP多肽的cDNA的表达载体。 ULBP多肽可以被分离或合成并用于制备针对多肽的抗体,特别是单克隆抗体。 抗体又可用于检测人细胞样品中ULBP多肽的存在,这可与患者中恶性病症的存在相关。 ULBP多肽刺激IFN-γ产生,NK细胞增殖和CTL活性。

    Use of integrin antagonists to inhibit angiogenesis
    4.
    发明授权
    Use of integrin antagonists to inhibit angiogenesis 失效
    使用整联蛋白拮抗剂抑制血管发生

    公开(公告)号:US07074408B2

    公开(公告)日:2006-07-11

    申请号:US09792200

    申请日:2001-02-23

    IPC分类号: A61K35/00 A61K38/00

    摘要: The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.

    摘要翻译: 本发明提供用于抑制整联蛋白的生物学活性的方法和组合物,用于抑制内皮细胞迁移。 并用于抑制血管发生。 特别地,本发明提供包含ADAM去整合素结构域的组合物和使用所述组合物的方法。 在优选的实施方案中,本发明的方法和组合物用于抑制血管发生和治疗由血管发生介导的疾病或病症。

    ULBP DNA and polypeptides
    5.
    发明授权
    ULBP DNA and polypeptides 失效
    ULBP DNA和多肽

    公开(公告)号:US06774224B2

    公开(公告)日:2004-08-10

    申请号:US10212507

    申请日:2002-08-05

    IPC分类号: C07H2100

    摘要: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-&ggr; production, NK cell proliferation, and CTL activity.

    摘要翻译: 本发明涉及纯化和分离的新型ULBP多肽,编码此类多肽的核酸,生产此类多肽的重组形式的方法,针对这些多肽产生的抗体,衍生自这些多肽的片段化肽以及上述用途。 ULBP多肽可以在人B细胞淋巴瘤的表面上发现。 提供分离或纯化形式的ULBP多肽的哺乳动物形式。 此外,提供了编码ULBP多肽的分离的核酸和包含编码ULBP多肽的cDNA的表达载体。 ULBP多肽可以被分离或合成并用于制备针对多肽的抗体,特别是单克隆抗体。 抗体又可用于检测人细胞样品中ULBP多肽的存在,这可与患者中恶性病症的存在相关。 ULBP多肽刺激IFN-γ产生,NK细胞增殖和CTL活性。

    Ligand for CD7 and methods for use thereof
    6.
    发明授权
    Ligand for CD7 and methods for use thereof 失效
    CD7配体及其使用方法

    公开(公告)号:US06762030B2

    公开(公告)日:2004-07-13

    申请号:US09997165

    申请日:2001-11-27

    IPC分类号: G01N3353

    摘要: The invention relates to CD7 and the discovery of its cognate ligand, the K12 protein, and the identification and cloning of polynucletides that encode the murine homolog of the human K12. Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the interaction between CD7 and K12. The use of the antagonists and agonists, including soluble K12 proteins, as therapeutics to treat diseases modulated by CD7 are also disclosed.

    摘要翻译: 本发明涉及CD7及其同源配体K12蛋白的发现,以及编码人K12的鼠同源物的多核苷酸的鉴定和克隆。 还公开了筛选候选分子以确定CD7和K12之间相互作用的潜在拮抗剂和激动剂的方法。 还公开了使用拮抗剂和激动剂,包括可溶性K12蛋白作为治疗由CD7调节的疾病的治疗剂。